title: Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota.
abstract: K-Ras mutations are frequently found in various cancers and are associated with resistance to treatment or poor prognosis. Similarly, poor outcomes have recently been observed in cancer patients with overexpression of protein kinase C iota (PKCiota), an atypical protein kinase C that is activated by oncogenic Ras protein and is required for K-Ras-induced transformation and colonic carcinogenesis in vivo. Thus far, there is no effective agent for treatment of cancers with K-Ras mutations or PKCiota overexpression. By synthetic lethality screening, we identified a small compound (designated oncrasin-1) that effectively kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations. The cytotoxic effects correlated with apoptosis induction, as was evidenced by increase of apoptotic cells and activation of caspase-3 and caspase-8 upon the treatment of oncrasin-1 in sensitive cells. Treatment with oncrasin-1 also led to abnormal aggregation of PKCiota in the nucleus of sensitive cells but not in resistant cells. Furthermore, oncrasin-1-induced apoptosis was blocked by siRNA of K-Ras or PKCiota, suggesting that oncrasin-1 is targeted to a novel K-Ras/PKCiota pathway. The in vivo administration of oncrasin-1 suppressed the growth of K-ras mutant human lung tumor xenografts by >70% and prolonged the survival of nude mice bearing these tumors, without causing detectable toxicity. Our results indicate that oncrasin-1 or its active analogues could be a novel class of anticancer agents, which effectively kill K-Ras mutant cancer cells.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.forename: Shuhong
authors.initials: S
authors.lastname: Wu
authors.forename: Jinsong
authors.initials: J
authors.lastname: Liu
authors.forename: Bingliang
authors.initials: B
authors.lastname: Fang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D005260:Female; D011905:Genes, ras; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007527:Isoenzymes / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D051379:Mice; D009154:Mutation; D011493:Protein Kinase C / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D023041:Xenograft Model Antitumor Assays; D018631:ras Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D000099293:Protein Kinase C-lambda
chemical_list: D007211:Indoles; D007527:Isoenzymes; D011493:Protein Kinase C; D034741:RNA, Small Interfering; D018631:ras Proteins; D000099293:Protein Kinase C-lambda; C532252:oncrasin-1
references.citation: Cell. 1997 Mar 7;88(5):593-602
references.pmid: 9054499
references.citation: Science. 1998 Jan 30;279(5351):707-10
references.pmid: 9445476
references.citation: Science. 1998 Jan 30;279(5351):710-4
references.pmid: 9445477
references.citation: Mol Cell Biol. 2004 Jul;24(14):6311-23
references.pmid: 15226433
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24
references.pmid: 16116079
references.citation: Genetics. 1946 May;31:269-90
references.pmid: 20985721
references.citation: Cell Mol Life Sci. 2005 Oct;62(19-20):2382-9
references.pmid: 16179969
references.citation: Nat Rev Mol Cell Biol. 2005 Feb;6(2):167-80
references.pmid: 15688002
references.citation: Nature. 1994 Aug 18;370(6490):527-32
references.pmid: 8052307
references.citation: Nat Rev Cancer. 2005 Sep;5(9):689-98
references.pmid: 16110319
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4454-8
references.pmid: 8633088
references.citation: Cancer Res. 2000 Oct 1;60(19):5359-64
references.pmid: 11034071
references.citation: Science. 1998 Sep 25;281(5385):2042-5
references.pmid: 9748166
references.citation: Nature. 1987 May 28-Jun 3;327(6120):293-7
references.pmid: 3587348
references.citation: Cell. 1993 Aug 13;74(3):555-63
references.pmid: 7688666
references.citation: Cancer Res. 2005 Oct 1;65(19):8905-11
references.pmid: 16204062
references.citation: Cell. 2000 Dec 8;103(6):931-43
references.pmid: 11136978
references.citation: Cancer Res. 2002 Dec 15;62(24):7154-6
references.pmid: 12499248
references.citation: Oncogene. 2001 May 24;20(23):2927-36
references.pmid: 11420705
references.citation: Cancer Res. 2006 Apr 15;66(8):3992-5
references.pmid: 16618717
references.citation: Semin Oncol. 2004 Feb;31(1 Suppl 1):28-39
references.pmid: 14981578
references.citation: Cancer Res. 2000 Dec 1;60(23):6597-600
references.pmid: 11118040
references.citation: Cell. 2000 Oct 13;103(2):227-38
references.pmid: 11057896
references.citation: J Biol Chem. 1993 Jan 5;268(1):13-6
references.pmid: 8380153
references.citation: J Cell Biol. 2004 Mar 15;164(6):797-802
references.pmid: 15024028
references.citation: Clin Cancer Res. 1996 Feb;2(2):411-8
references.pmid: 9816185
references.citation: J Cell Biochem. 2002;85(1):42-53
references.pmid: 11891849
references.citation: J Biol Chem. 1994 Dec 16;269(50):31706-10
references.pmid: 7989344
references.citation: N Engl J Med. 1988 Sep 1;319(9):525-32
references.pmid: 2841597
references.citation: J Biol Chem. 1997 May 30;272(22):14459-64
references.pmid: 9162087
references.citation: Cancer Res. 2004 Mar 1;64(5):1655-63
references.pmid: 14996724
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8
references.pmid: 2359137
references.citation: Oncogene. 1999 Apr 22;18(16):2537-46
references.pmid: 10353597
references.citation: Cell. 1994 Jun 17;77(6):829-39
references.pmid: 8004672